Table 1. Clinical characteristics of... | American Society of Hematology

Table 1.

Clinical characteristics of recipients (n = 6) and outcomes after transplantation

	Patient
	1	2	3	4	5	6
Age, y	65	56	38	51	57	62
Sex	F	F	M	M	M	M
Disease	Myeloma	Myeloma	NHL	Myeloma	Myeloma	Myeloma
Renal disease	Myeloma	Myeloma	Unknown	Myeloma	Myeloma	Myeloma
RRT	Yes	Yes	Yes	Yes	Yes	Yes
Prior ASCT	Yes	Yes	No	Yes	No	Yes
Disease status	CR	VGPR	CR	CR	VGPR	CR
Time since diagnosis, mo	27	24	44	55	12	30
Conditioning	ATG/Cy/TBI	Flu/Cy/TBI	Flu/Cy/TBI	Flu/Cy/TBI	Flu/Cy/TBI	Flu/Cy/TBI
Donor	Son	Sister	Mother	Brother	Son	Sister
HLA match	3/6	3/6	3/6	3/6	3/6	3/6
HSC source	Marrow	Marrow	Marrow	Marrow	PBSCs	Marrow
CD34 per kg	2.62 × 10⁶	2.06 × 10⁶	4.58 × 10⁶	1.67 × 10⁶	3.01 × 10⁶	0.94 × 10⁶
Engraftment, d
Neutrophils	15	17	26	22	20	28
Platelets	48	31	—	41	32	39
Return to RRT	No	No*	Yes	No	No	No
d-30 chimerism, %†
All cell	<10	>97	>98	100	100	96
CD3⁺	<2	NA‡	>96	100	100	NA‡
d-100 chimerism, %†
All cell	0	100	>97	100	NA‡	NA‡
CD3⁺	0	100	NA‡	100	NA‡	NA‡
1-y chimerism, %†
All cell	0	100	—	NA‡	100	100
CD3⁺	0	100	—	NA‡	100	100
Acute GVHD	No	Grade 1	No	No	Grade 1	No
Chronic GVHD	No	No	—	Moderate	Moderate	No
1-y OS	Alive	Alive	Died (d 142)	Alive	Alive	Alive
1-y disease status	CR	CR	—	CR	CR	CR
IST	Yes	No	—	No	Yes	No
1-y serum Cr, mg/dL	0.87	0.92	—	1.04	1.12	1.45
Follow-up, mo	73	48 (died)	—	46	34	12
Most recent serum Cr, mg/dL	0.78	—	—	1.04	1.00	1.45

	Patient
	1	2	3	4	5	6
Age, y	65	56	38	51	57	62
Sex	F	F	M	M	M	M
Disease	Myeloma	Myeloma	NHL	Myeloma	Myeloma	Myeloma
Renal disease	Myeloma	Myeloma	Unknown	Myeloma	Myeloma	Myeloma
RRT	Yes	Yes	Yes	Yes	Yes	Yes
Prior ASCT	Yes	Yes	No	Yes	No	Yes
Disease status	CR	VGPR	CR	CR	VGPR	CR
Time since diagnosis, mo	27	24	44	55	12	30
Conditioning	ATG/Cy/TBI	Flu/Cy/TBI	Flu/Cy/TBI	Flu/Cy/TBI	Flu/Cy/TBI	Flu/Cy/TBI
Donor	Son	Sister	Mother	Brother	Son	Sister
HLA match	3/6	3/6	3/6	3/6	3/6	3/6
HSC source	Marrow	Marrow	Marrow	Marrow	PBSCs	Marrow
CD34 per kg	2.62 × 10⁶	2.06 × 10⁶	4.58 × 10⁶	1.67 × 10⁶	3.01 × 10⁶	0.94 × 10⁶
Engraftment, d
Neutrophils	15	17	26	22	20	28
Platelets	48	31	—	41	32	39
Return to RRT	No	No*	Yes	No	No	No
d-30 chimerism, %†
All cell	<10	>97	>98	100	100	96
CD3⁺	<2	NA‡	>96	100	100	NA‡
d-100 chimerism, %†
All cell	0	100	>97	100	NA‡	NA‡
CD3⁺	0	100	NA‡	100	NA‡	NA‡
1-y chimerism, %†
All cell	0	100	—	NA‡	100	100
CD3⁺	0	100	—	NA‡	100	100
Acute GVHD	No	Grade 1	No	No	Grade 1	No
Chronic GVHD	No	No	—	Moderate	Moderate	No
1-y OS	Alive	Alive	Died (d 142)	Alive	Alive	Alive
1-y disease status	CR	CR	—	CR	CR	CR
IST	Yes	No	—	No	Yes	No
1-y serum Cr, mg/dL	0.87	0.92	—	1.04	1.12	1.45
Follow-up, mo	73	48 (died)	—	46	34	12
Most recent serum Cr, mg/dL	0.78	—	—	1.04	1.00	1.45

Abbreviations: ASCT, autologous stem cell transplantation; CR, complete remission; Cr, creatinine; Cy, cyclophosphamide; Flu, fludarabine; HSC, hematopoietic stem cell; IST, immunosuppressive therapy; NA, not applicable; NHL, non-Hodgkin lymphoma; OS, overall survival; PBSC, peripheral blood stem cell; RRT, renal replacement therapy; TBI, total-body irradiation; VGPR, very good partial response.

Required RRT after 3 y because of relapse of multiple myeloma.

†

Chimerism is expressed as percentage of cells that are of donor origin.

‡

NA refers to time points where purity of cell population was inadequate to perform assay or it was not performed.

View Large

This Feature Is Available To Subscribers Only